Keyphrases
Dual Specificity
100%
Multiple Myeloma
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Associated Antigen
28%
Lymphocytes
14%
Cell Activity
14%
Response Rate
14%
Single Antigen
14%
Low Activity
14%
Nondurables
14%
Tumor
14%
T Cell Activation
14%
Myeloma Cells
14%
CD38
14%
Receptor Targets
14%
Median Survival
14%
CD138
14%
Target Antigen
14%
Healthy Tissue
14%
Leukemia-lymphoma
14%
Primary Cells
14%
Alternative Therapy
14%
Chimeric Antigen Receptor T-cell Therapy
14%
Safer Alternatives
14%
B-cell Leukemia
14%
Normal Human Tissues
14%
Off-target Toxicity
14%
NSG Mice
14%
B-cell Maturation Antigen
14%
Immunology and Microbiology
Multiple Myeloma
100%
Chimeric Antigen Receptor T-Cell
100%
Chimeric Antigen Receptor
42%
B Cell
14%
Normal Human
14%
CD38
14%
Immunotherapy
14%
Human Tissue
14%
Chimeric Antigen Receptor T-Cell Therapy
14%
T Cell Activation
14%
Multiple Myeloma Cell Line
14%
NSG Mouse
14%
B Cell Maturation Antigen
14%
Lymphocyte
14%
Medicine and Dentistry
Multiple Myeloma
100%
Chimeric Antigen Receptor T-Cell
100%
Chimeric Antigen Receptor
42%
In Vitro
14%
Neoplasm
14%
T Cell Activation
14%
Immunotherapy
14%
Human Tissue
14%
Multiple Myeloma Cell Line
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
B Cell Leukemia
14%
B Cell Maturation Antigen
14%
Lymphocyte
14%